Is aging something we can actually control—or even reverse? One Silicon Valley startup says yes, and it’s now raised $130 million to prove it.
Retro Biosciences, a stealthy longevity company founded by Coinbase CEO Brian Armstrong, is betting big on a single thesis: that aging is not inevitable. The startup recently emerged from semi-anonymity with fresh funding and an audacious claim—aging is malleable, and science is finally catching up.
Backed by a who’s-who of tech-world believers and with a war chest to match, Retro is promising breakthroughs that could radically extend human healthspan. But is there real science behind the optimism?
Aging, redefined
Retro’s core argument is built around a radical reframing of aging—not as a fixed biological process, but as a disease-like condition that can be slowed, paused, or even reversed. Its mission is to “add 10 healthy years to every person’s life” by tackling the biological underpinnings of age-related decline.
So far, the company is pursuing three main approaches:
-
Reprogramming cells to reset them to a more youthful state.
-
Plasma-inspired therapeutics, based on research that suggests factors in young blood can rejuvenate older tissue.
-
Autophagy stimulation, targeting how cells clean out damage.
All of these ideas have scientific roots. But none are slam-dunk proven—yet.
Who’s behind it
Retro was quietly launched in 2021 with Armstrong’s initial $105 million commitment, a rare move that signaled how personally invested the crypto billionaire is in the project. The company is led by CEO Joe Betts-LaCroix, a biotech veteran and former Calico researcher, along with a team of scientists poached from top academic labs.
In recent months, it raised an additional $130 million in venture funding, led by investors who believe the next frontier of health tech isn’t treating disease, but preventing the biological causes of aging itself.
The scientific backdrop
So, does science actually back up Retro’s pitch?
Yes—and no.
The concept of cellular reprogramming made global headlines in 2012 when scientist Shinya Yamanaka won a Nobel Prize for discovering how to revert mature cells to stem-cell-like states using “Yamanaka factors.” That same concept is now being explored as a way to make old cells act young again without triggering cancer.
Similarly, young blood plasma studies—like the famous Stanford parabiosis experiments—have shown that old mice infused with young plasma exhibit improved cognition and muscle strength. It’s a seductive idea, though still controversial and far from clinical readiness.
Autophagy, meanwhile, is a more established target. Fasting, exercise, and certain compounds like spermidine and rapamycin can enhance the cell’s natural “recycling” process. Longevity researchers agree that improving autophagy could be a key pathway to extending healthspan.
In short: Retro’s science is grounded in early but promising research. The challenge is turning that into actual products that pass clinical trials.
The business of living longer
The longevity space is booming. Global investors have poured billions into startups chasing aging-related breakthroughs—from supplements to gene therapies to AI-powered diagnostics.
Retro’s $130 million raise puts it among the top-funded players, just behind Altos Labs, the reprogramming-focused megastartup reportedly backed by Jeff Bezos, and Calico, Google’s mysterious anti-aging moonshot.
But unlike those secretive giants, Retro is starting to go public with its vision, hiring aggressively and publishing papers in open-access journals. The company says it wants to set a new benchmark for transparency and rigor in the longevity space.
What’s next
Retro’s first real-world tests are still a few years out, but the startup is moving quickly. Insiders say the company will likely prioritize therapeutics targeting midlife cellular decline—hoping to build an on-ramp to treating aging before disease ever sets in.
Whether or not that vision pans out, one thing is clear: Retro’s model is challenging a trillion-dollar health care industry that still treats symptoms instead of root causes. And it’s betting that millennials and Gen Z, raised on wellness and wearables, will be the first to embrace preventive aging interventions.
In the words of one Retro advisor: “We’re not just trying to extend life. We’re trying to upgrade it.”
